Novo-Nordisk stock: November 4 is the next date for Novo-Nordisk stock

Published on 10/19/2026 at 16:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo-Nordisk is 35.67 percent below its EUR 53.46 high. Novo-Nordisk stock costs EUR 34.39 on October 19, 2026, down 0.29 percent versus Xetra close.

Reporting date and valuation

Novo-Nordisk is scheduled to report third-quarter results on November 4, 2026.
The stock stands 35.67 percent below its EUR 53.46 52-week high.
Novo-Nordisk stock costs EUR 34.39 at Lang & Schwarz on October 19, 2026 at 4:36 p.m. CEST, minus 0.29 percent versus the Xetra close of October 16, 2026.
Novo Nordisk has a price-to-earnings ratio of 9.79 and a dividend yield of 0.05 percent.

Forscherin im Laborkittel an Pipette, Schwarzweiß-Reportagefoto, Labor — Novo Nordisk A/S (DK0062498333): Forscherin im Labor-Kittel bedient Pipette in dokumentarischem Schwarzweiß-Reportagefoto, Illustration mit AI erstellt.

Novo-Nordisk (DK0062498333) is scheduled to publish its third-quarter results on November 4, 2026, according to Yahoo Finance. Novo-Nordisk stock was trading at EUR 34.39 at Lang & Schwarz on October 19, 2026 at 4:36 p.m. CEST, minus 0.29 percent versus the Xetra close of October 16, 2026 at EUR 34.49.

Distance from the yearly high

The stock stands 35.67 percent below its 52-week high of EUR 53.46 and 13.12 percent above its 52-week low of EUR 30.40, with both levels dated October 19, 2026. The gap to the high keeps the longer-term price frame more important than the small intraday move.

Today's range remains narrow

Novo-Nordisk traded between EUR 34.27 and EUR 34.72 during the October 19 session. The bid was EUR 34.39 and the ask EUR 34.40, while volume was 1,723,368 shares at the latest available home-market quote dated October 19, 2026.

Valuation and the next date

Novo Nordisk had a market capitalization of USD 170.9 billion, a price-to-earnings ratio of 9.79 and a dividend yield of 0.05 percent as of October 19, 2026. The next scheduled reporting date is November 4, 2026, so the upcoming quarterly release is the next defined calendar marker for the stock.

Comparison with peers

Novo Nordisk: minus 0.29 percent, P/E 9.79, market capitalization USD 170.9 billion.

Eli Lilly (NYSE, USD): minus 0.74 percent, P/E 41.97, market capitalization USD 1,174.5 billion.

AstraZeneca (Nasdaq, USD): minus 0.15 percent, P/E 24.73, market capitalization USD 256.1 billion.

The price remains the signal

The narrow daily change contrasts with the stock's 35.67 percent distance from its yearly high. For investors, the November 4 reporting date and the valuation gap provide the clearest reference points for the next market reaction.

The further course of trading is shown by the continuously updated real-time quote of Novo-Nordisk stock.